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A growing tradition of laboratory animal use 
 
Researchers have sought to understand the mechanisms of human health and disease, as long as the latter has 
existed. Serious interest in the structure and functioning of the human body has been evident at least since the 
ancient Greeks. However, the investigations of Greek physicians into human anatomy and physiology were 
greatly hampered by social taboos about dissecting human corpses (von Staden, 1989). But non-human animals 
(hereinafter, animals), were not so revered – or feared: some dissected their corpses, while others, such as 
Alcmaeon of Croton (6th–5th Century BCE), practiced surgical or other invasive procedures on the living (Court, 
2005; Maehle and Tröhler, 1990), and conducted some of the first animal experiments ever recorded.  
 
Almost two millennia passed before such social dogmas were seriously questioned. The Renaissance heralded a 
new era of scientific inquiry, during which Flemish physician and surgeon Vesalius (1514–1564) began to illegally 
source human cadavers for dissection. He discovered that a number of anatomical structures believed to exist, 
following animal dissections, were unexpectedly absent in humans. His highly accurate anatomical descriptions 
challenged the authoritative texts of classical authors (O’Malley, 1964).  
 
Throughout the 17th Century the spirit of scientific inquiry grew, and with it, experimentation on living animals. 
Some surgical investigations and demonstrations that predated anesthesia were infamously cruel, and caused 
widespread social controversy. However, French philosopher René Descartes (1596–1650) famously rebutted 
such critiques, claiming that animals were merely mindless automata, i.e. ‘machine-like’ (Descartes, 1989), 
whose cries were of no greater moral consequence than the squeals of a poorly oiled machine.  
 
Nevertheless, by the end of the 17th Century the question of animal suffering and the acceptability of such 
procedures had become an increasingly prominent moral and social concern (Maehle and Tröhler, 1990). Jeremy 
Bentham (1748 – 1832), famously asked, “The question is not, Can they reason? nor, Can they talk? but, Can they 
suffer?” (Bentham, 1823: Chap. 17, footnote). And his concerns have been echoed by many others since. 
 
By the beginning of the 19th Century, a revolution had begun within medicine. Growing awareness of the poor 
effectiveness of many traditional therapies led to investigations focused on understanding disease etiology 
(causation) and pathogenesis (progression), with the intention of increasing diagnostic and prognostic accuracy, 
and treatment efficacy. The use of animals as investigative models increased in the second half of the 19th 
Century, often in highly invasive research, and still predating most forms of anesthesia or analgesia. Increasing 
social unease about such research led to widespread opposition in Europe, and especially Britain, where 
organizations such as the National Anti-Vivisection Society (founded 1875, NAVS 2012) and British Union for the 
Abolition of Vivisection (founded 1898, CFI, n.d.; now Cruelty Free International) were established to campaign 
against it. The Cruelty to Animals Act (1876) entered into force, becoming the first legislation to regulate animal 
experiments (Franco, 2013). 
 
In the latter part of the 20th Century, social concerns about animal suffering continued to grow, accompanied by 
a seemingly inexorable rise in animal experimentation. Currently, the most accurate evidence-based estimates 
of global laboratory animal use describe the year 2005. Approximately 126.9 million non-human vertebrates 
were used worldwide in that year (Knight, 2008a; Taylor et al., 2008). And driven by increased development and 
use of genetically-modified animals (Ormandy, Schuppli and Weary, 2009), and by large-scale chemical testing 
programs (Knight, 2011), laboratory animal use has steadily increased in most developed countries, ever since. 
 
The single largest category of research conducted today is fundamental biological research, much of which has 
no obvious application. The European Union is the world’s largest region that publishes comprehensive analyses 
of its laboratory animal use. At the time of writing, the most recent published figures describe animal use in the 
27 Member States of the EU in 2011 (with one state reporting for 2010). Within this period, 46.1% of the 11.5 
million animals were used for this purpose. However, barring 1.6% of animals used for education and training, 
nearly all of the remaining 52.3% were used in attempts to advance public health – whether for research, 
development, toxicity testing or quality control of products and devices for human or veterinary medicine and 
dentistry, or for disease diagnosis, or other purposes (EC, 2013). And nearly all of these animals would have been 
used in attempts to advance human, rather than animal, health.  
 
Effectiveness of laboratory animal use 
 
Combined, this represents an enormous commitment of animal, scientific, personnel and financial resources, 
ostensibly dedicated primarily to the advancement of human health. But how effective has all this research 
been? 
 
Advocates of such research have regularly claimed it is essential for preventing, curing, or alleviating human 
diseases (e.g., Brom, 2002; Festing, 2004), and further, that the greatest achievements of medicine have only 
occurred through the use of animals (e.g., Pawlik, 1998). However, those who champion such claims frequently 
have careers dependent on such research. Furthermore, counter-narratives by others contest the contributions 
or necessity of such research for the advancement of medical progress (e.g., Greek and Greek, 2002). 
 
To support their argument, advocates on either side regularly cite cases in which animal and human outcomes 
are similar or different. However, only small numbers of experiments are normally included in such reviews, and 
their selection may be subject to bias. These are known as narrative reviews. 
 
To provide more definitive conclusions, systematic reviews of the human clinical or toxicological utility of large 
numbers of animal experiments are necessary. A systematic review is “...a review of a clearly formulated 
question that uses systematic and explicit methods to identify, select, and critically appraise relevant research, 
and to collect and analyze data from the studies that are included in the review. Statistical methods (meta-
analysis) may or may not be used to analyze and summarize the results of the included studies” (Moher et al., 
2009).  
 
In recent years, systematic reviews have become widely utilized to investigate a broad range of clinical and other 
research questions. Their aims are to retrieve as much high quality evidence as possible relevant to the research 
question, and to minimize bias during the selection, analysis and reporting of results. Any conclusions reached 
should accordingly be as close as possible to biological, physical, chemical or other truths. 
 
A large number of systematic reviews of animal experiments within various research fields have examined their 
utility for advancing human healthcare, and the results have not been good. Of 20 published systematic reviews 
examining human clinical utility located during a comprehensive literature search, animal models demonstrated 
significant potential to contribute toward clinical interventions in only two cases, one of which was contentious. 
Included were experiments approved by ethics committees on the basis of claims that medical advances were 
likely to result, highly-cited experiments published in leading journals, and chimpanzee experiments – utilizing 
the species most generally predictive of human outcomes. Seven additional reviews failed to demonstrate utility 
in reliably predicting human toxicological outcomes, including those associated with the greatest public health 
concerns, such as carcinogenicity and teratogenicity. Results in animal models were frequently equivocal, or 
inconsistent with human outcomes (Knight, 2011). 
 
Since then, numerous additional reviews have yielded similar results. Baker and colleagues (2014), for example, 
examined human neurological disease, which has been extensively studied in animal models, with relatively few 
human treatments arising (Cheeran et al., 2009; Vesterinen et al., 2010). Similarly, despite reports of efficacy of 
over 1,000 treatments in animal models of multiple sclerosis (MS), very few treatments have progressed to the 
marketplace (Vesterinen et al., 2010). This usually indicates failures of efficacy, or safety concerns in humans. 
And despite the widespread use of animal models within stroke research, virtually no interventions described as 
effective in animal models have proven similarly effective in human patients (Cheeran et al., 2009). There are 
many other examples. 
 
Several studies have sought to determine the maximal human clinical utility that might be achieved by animal 
models, either by examining chimpanzee experiments, given that chimpanzees are our closest relatives (Knight, 
2007), or experiments approved by ethics committees on the basis of explicit claims of likely human healthcare 
benefits (Lindl, Völkel and Kolar, 2005), or by examining highly cited animal experiments published in leading 
scientific journals (Hackam and Redelmeier, 2006). In the latter case, for example, 76 animal experiments were 
located, each of which had been cited well over 500 times, and published in one of the world’s seven top scientific 
journals when ranked by journal impact factor. Hence, these experiments represented much of the most 
important and scientifically interesting animal research published at the time. In only 28 cases (36.8%), animal 
results were later replicated in humans. Most animal research is neither highly cited nor published in world 
leading journals, and successful translation to humans is far lower. 
 
Limitations of animal models 
 
A variety of factors appear responsible for the poor rates of translation of outcomes from animal studies into 
human patients and consumers. These relate both to the animal models themselves, and to the ways in which 
they are used. 
 
Fundamental biochemical differences between species may result in differences in absorption, distribution, 
metabolism, and elimination pathways or rates, which may alter toxico- or pharmacokinetics (i.e. bodily 
distribution). Toxico- and pharmacodynamics (mechanisms of action and biological effects) may also be altered. 
Jointly these factors may contribute to differences in organ systems affected, and in the nature and magnitude 
of those effects (Hartung, 2008; Knight, 2011). 
 
Further problems arise from the characteristics of the animals used. Biological variability and predictivity for 
humans are frequently compromised by restriction to single rodent strains, young animals, and single sexes, 
usually without concurrent human risk factors, such as common co-morbidities, which can alter human 
responses to exogenous (externally-derived) compounds (Hartung, 2008; Knight, 2011). 
 
Additional problems arise from the ways in which the animals are used. Many toxicity tests, for example, rely on 
maximum tolerated doses (above which acute toxicity-related effects preclude further dosing), and chronic 
dosing. These factors maximize sensitivity to toxins, with the result that false negative results rarely occur. 
However, these conditions can also overwhelm the physiological defenses which are effective at environmentally 
realistic doses, resulting in false positive outcomes. As a result, many compounds which would not normally be 
considered toxic, are falsely indicated as such, by animal tests – which substantially decreases the reliability and 
relevance of any positive result. Additionally, important human routes of exposure (e.g. inhaled) may differ from 
those tested in animals, requiring extrapolation between routes of exposure, as well as between species, 
introducing further uncertainty (Gold, Slone and Ames, 1998; Hartung, 2008; Knight, 2011). 
 
Additionally, animals used in laboratories commonly experience a significant array of stressors. These include 
stresses incurred during handling, restraint, and other routine laboratory procedures, and particularly, the 
stressful routes of dose administration common to toxicity tests. Orogastric gavaging, for example, involves the 
insertion of a tube into the esophagus for the forced administration of test compounds. Combined with 
environmental stressors (e.g. due to limited space and environmental enrichment) and social stressors (e.g. due 
to aggressive interactions between conspecifics), these represent a significant body of stressors. These can alter 
physiological, hormonal, and immune status, and even cognitive capacities and behavioral repertoires, in ways 
which are not always predictable (Balcombe, Barnard and Sandusky, 2004; Balcombe, 2006; Baldwin and Bekoff, 
2007). The results may include alterations in the progression of diseases, in bodily responses to chemicals and 
test pharmaceuticals, and in a range of other scientific outcomes, such as those dependent on accurate 
determination of physiological, behavioral, or cognitive characteristics. 
 
Methodological quality of animal studies 
 
As if these weren’t problem enough, a sizeable body of recent studies and systematic reviews have confirmed 
the existence of significant methodological flaws, in most published animal experiments (e.g. Knight 2008b).  
 
Indeed, to date no systematic reviews appear to have been published in which a majority of animal studies that 
were assessed against appropriate objective criteria, were found to have been of good methodological quality. 
 
In particular, a variety of design features must be included within animal experiments, to minimize the potential 
for bias. Hooijmans et al. (2014) described 10 types of bias that have the potential to influence animal 
experimental results, which they grouped into selection bias, performance bias, detection bias, attrition bias, 
reporting bias, and other sources of bias. 
 
Many of these flaws are highly prevalent within animal studies. Kilkenny and colleagues (2009) conducted one 
of the largest and most comprehensive systematic surveys to date, assessing the experimental design, statistical 
analysis and reporting of published animal experiments. 271 papers were examined, which included 72 studies 
using mice, 86 using non-human primates and 113 using rats. Almost all (99%; 269/271) of these papers were 
published between 2003 and 2005. They covered a wide variety of experimental fields, were published in a 
comprehensive range of journals, and were funded by leading grant agencies bodies within the UK and US. 
 
However, only 59% of these studies clearly stated the hypothesis or objective of the study, and the number and 
characteristics of the animals used. Details such as animal strain, sex, age and weight are all scientifically 
important and can potentially influence results (Alfaro, 2005; GV-Solas, 1985; Obrink and Rehbinder, 2000). 
Nevertheless, in many cases these were omitted. 
 
Knowledge of planned treatment (or lack, thereof) is one of a number of factors that can unconsciously influence 
the assignment of animals to treatment groups, e.g., when researchers sympathetically select animals they 
consider weaker, to be used as controls, rather than test animals. The introduction of such confounding factors 
(in this case, variable animal fitness), can potentially bias results (in this case, selection bias has occurred). 
Accordingly, randomized selection of animals for treatment groups is mandated, to ensure that outcome 
differences are most likely due to treatment effects (Festing and Altman, 2002; Festing et al., 2002). Haphazard 
selection does not give sufficient certainty that results are truly random, so a systematic approach is necessary, 
such as the use of a random number generator (Kilkenny et al., 2009). Nevertheless, despite its well-
acknowledged importance, randomized allocation of animals to test groups was reported in only 12% of these 
studies. 
 
Another crucial feature of good experimental design concerns the assessment of outcomes. Where qualitative 
assessments occur, which involve assessor judgements, it is similarly crucial that assessors do not know (are 
‘blinded’ to) the treatment (or lack, thereof), of animals assessed – lest such knowledge subtly affect their 
judgement (Festing and Altman, 2002). Because, as Cochrane (1972) noted, ‘‘When humans have to make 
observations there is always the possibility of bias’’ – even unintentional bias. Nevertheless, only 14% (5/35) of 
all papers in the survey by Kilkenny et al. (2009) that reported qualitative assessment of outcomes, also reported 
the use of blinding. 
 
Many factors can affect experimental outcomes, so the incorporation of measures to minimize sources of bias 
are crucial to ensuring the reliability of research results. And yet, 87% of papers examined by Kilkenny and 
colleagues failed to report randomization during animal selection, and 86% failed to report blinded assessment 
of outcomes. Additionally, only 70% of the publications that used statistical methods described their methods 
and presented the results with a measure of error or variability.  
 
More recently, similar results were found in an even larger study. Vogt et al. (2016) determined the prevalence 
of seven basic measures against bias (allocation concealment, blinding, randomization, sample size calculation, 
inclusion/exclusion criteria, primary outcome variable, and statistical analysis plan), within 1,277 experimental 
applications approved by Swiss authorities in 2008, 2010 and 2012, and also within 50 subsequent publications. 
Measures against bias were reported at very low rates both in experimental applications (2 – 19%) and in 
subsequent publications (0 – 34%). 
 
The importance of randomization and blinding when comparing two or more experimental groups has been 
highlighted by reviews of animal research in the field of emergency medicine, which have found that estimates 
of treatment efficacy were significantly reduced, in studies that incorporated these mechanisms to reduce risks 
of bias (Bebarta, Luyten and Heard, 2003; Macleod et al., 2008). Similar results have been found in numerous 
other studies. In fact, those incorporating the fewest measures to minimize sources of bias tended to report the 
greatest effect sizes (Crossley et al., 2008; Hirst et al., 2014; Macleod et al., 2005; Rooke et al., 2011; Vesterinen 
et al., 2010). The widespread failure to utilize mechanisms such as randomization and blinding appears to result 
in false expectations of treatment efficacy, with the results that reported outcomes in animals often fail to 
translate into humans. 
 
Similar results were reported following a literature review by Holman, Head, Lanfear and Jennions (2015). They 
found that blind protocols are uncommon in the life sciences, and that non-blind studies tend to report more 
significant outcomes and higher effect sizes. They noted that: “Observer bias and other “experimenter effects” 
occur when researchers’ expectations influence study outcome. These biases are strongest when researchers 
expect a particular result, are measuring subjective variables, and have an incentive to produce data that confirm 
predictions. To minimize bias, it is good practice to work “blind,” meaning that experimenters are unaware of 
the identity or treatment group of their subjects while conducting research” (p. 1). 
 
Another problem commonly observed by Kilkenny et al. (2009) concerned the transparency of reporting, and the 
robustness of statistical analysis. Almost 60% of surveyed publications were deficient in these areas. Most studies 
failed to provide sample sizes, or adequate justifications of these. And yet, studies that use too many animals 
waste animal lives. Conversely, the results of underpowered studies (with insufficient experimental subjects) 
cannot be extrapolated to wider populations, with sufficient certainty. Accordingly, power analyses or other 
simple calculations are widely used in human clinical trials, to ensure enough subjects (but not more) are present, 
to be able to detect biologically important effects. Indisputably, the same principles should apply to animal 
studies (Dell, Holleran and Ramakrishnan, 2002; Festing and Altman, 2002). 
 
Unfortunately, methodological flaws appear prevalent even within animal research conducted at highly ranked 
universities, and published in leading journals. After studying 814 randomly-selected studies reporting primary 
research, 2,671 publications reporting drug efficacy in eight disease models, and 4,859 publications from five UK 
institutions ranked highest across six units of assessment in biomedical sciences, in the 2008 national Research 
Assessment Exercise, Macleod and colleagues (2015) reported that severe deficiencies of experimental design 
remain the norm. These deficiencies were prevalent in research conducted at leading UK research universities, 
in research funded by leading UK funding organizations, and in research reported in high impact journals.  
 
Evidence-based research within human clinical trials 
 
The importance of sound experimental design, and particularly, the necessity of incorporating factors designed 
to minimize bias risks, have long been recognized within the field of human research. The Consolidated Standards 
of Reporting Trials (CONSORT) Statement for randomized controlled human clinical trials was one of the first 
guidelines developed to ensure the quality of human-based research. It provides an evidence-based, minimum 
set of recommendations, including a checklist of 25 recommended items, that should be included when reporting 
randomized human trials (Moher, Schulz and Altman, 2001; Schulz, Altman and Moher 2010). Since then, more 
than 90 guidelines have been developed for reporting different types of health research (see www.equator-
network.org, and Altman et al., 2008; Simera et al., 2010). 
 
An increasing number of leading journals have subsequently requested their authors comply with the CONSORT 
guidelines (Altman, 2005; Hopewell et al., 2008), and organizations commending the use of such guidelines 
include the Committee on Publication Ethics (n.d.), the Nuffield Council on Bioethics (2005), the Council of 
Science Editors (2009), and the International Committee of Medical Journal Editors (2015). Subsequent to the 
widespread endorsement of such guidelines, studies have indicated that the quality and transparency of reports 
of human clinical trials have improved (Plint et al., 2006; Kane, Wang and Garrard, 2007).  
 
Application to animal studies 
 
More recently, multiple attempts have been made to introduce similar standards within animal studies. In 2009, 
Kilkenny and colleagues observed that most biomedical journals provided little or no guidance about the 
reporting of animal research, other than the requirement to report ethical review of the proposed protocols. 
They noted the contrast between biomedical journals, and those within other several research areas – 
particularly medical research – in this respect. 
 
Accordingly, in 2010 Kilkenny and colleagues proposed the Animal Research: Reporting of In Vivo Experiments 
(ARRIVE) guidelines. Prepared in consultation with scientists, statisticians, journal editors, and research funders, 
these comprised a checklist of 20 items, designed to provide minimum information on items such as the number 
and specific characteristics of animals used (including species, strain, sex, and genetic background); housing and 
husbandry conditions; and the experimental, statistical, and analytical methods used. The latter points included 
measures to reduce bias, such as the random allocation of animals to experimental groups, blinded assessment 
of outcome measures, statistical justifications of sample sizes, reporting of animals excluded from analyses, and 
of exclusion criteria, and of any investigator conflicts of interest. The intention was that these items should be 
included within all scientific publications reporting animal research, thereby allowing critical assessment of 
methods used, and results obtained. 
 
Hooijmans and colleagues (2010) similarly proposed a Gold Standard Publication Checklist, which included 74 
items designed to improve the quality of animal studies, and to fully integrate 3Rs methods, and to facilitate 
their incorporation within systematic reviews and meta-analyses. 
 
In 2014, Hooijmans and colleagues also proposed a risk of bias (RoB) tool to assess methodological quality and 
risk of bias within animal studies. It was based on the similar Cochrane RoB tool (Higgins et al., 2011), and was 
adjusted for particular aspects of bias that play a role in animal studies.  
 
Other authors have proposed similar guidelines and checklists for the conduct and reporting of animal research. 
In 2009, Osborne and colleagues from the RSPCA (UK) proposed a 12 point assessment scheme for scoring 
biomedical journals’ policies on animal welfare and the 3Rs. And in 2015, Martins and colleagues proposed their 
Excellence in Editorial Mandatory Policies for Animal Research (EXEMPLAR) Scale, comprising four categories: 
regulatory compliance, quality of research and reporting of results, animal welfare and ethics, and criteria for 
exclusion of papers.  
 
Poor compliance of animal studies 
 
Such guidelines provide indisputable benefits in ensuring the reporting of methodological quality, reliability of 
results, and incorporation of 3Rs principles (i.e., the Replacement, Reduction and Refinement of animal 
research). The ARRIVE guidelines of Kilkenny and colleagues (2010) have been published or endorsed by over 
1,000 research journals (including those published by the Nature Publishing Group, PLoS, and BioMed Central) 
(Reichlin, Vogt and Würbel, 2016). They have been similarly endorsed by major UK funding agencies (including 
the Wellcome Trust, the Biotechnology and Biological Sciences Research Council, and the Medical Research 
Council), and they also form part of the US National Research Council Institute for Laboratory Animal Research 
guidelines (Baker et al., 2014). And yet, despite such widespread endorsement, a number of studies have 
demonstrated that compliance with such guidelines remains poor. 
 
Noting that “Despite reports of over 1,000 treatments effective in animal models of multiple sclerosis (MS), very 
few treatments have so far made it to the marketplace following initial development in disease-related animal 
models (Vesterinen et al., 2010)”, Baker and colleagues (2014) investigated the general adequacy of reporting 
within animal studies of MS. They uncovered significant inadequacies within the reporting of experimental 
design, including the selection of appropriate statistical analyses, and the application of key points in the ARRIVE 
guidelines. They observed that the ARRIVE guidelines are not being implemented by authors, reviewers, and 
journal editors (Baker and Amor, 2012; Landis et al., 2012; Schwarz, Iglhaut and Becker, 2012). 
 
Despite their very widespread publication and endorsement, lack of awareness of such guidelines appears to 
remain a major problem. After surveying all registered in vivo researchers in Switzerland recently, Reichlin et al. 
(2016) reported that among 302 self-selected participants, 56.3% did not know of the ARRIVE Guidelines. This 
302 (16%) of the 1,891 total comprised those who returned fully completed questionnaires and hence were not 
excluded. Even among those whose latest paper was published in a journal that had endorsed the ARRIVE 
guidelines, 51% had never heard of them.  
 
The failure of biomedical journals to insist on compliance with quality control standards is partly to blame. After 
surveying 236 biomedical journals’ policies on animal research, Osborne and colleagues (2009) found no mention 
of animal use within author guidelines or elsewhere, within 35% of journals studied. In 18% of journals animals 
were mentioned, but no perceptible guidelines were provided, and most of the remaining journals scored poorly, 
with 37% scoring three or fewer points out of 12 equally weighted items within their quality checklist. 
 
After examining 170 journals publishing studies on animal models of three human diseases, namely Amyotrophic 
Lateral Sclerosis (also known as Motor Neurone Disease), Type-1 Diabetes and Tuberculosis, Martins and 
colleagues (2015) found broadly similar results to those of Osborne and colleagues (2009), when assessing 
studies using their EXEMPLAR scale. They noted that, “little progress found regarding in-house policies on the 
ethical treatment of animals is worrisome” (p. 325). 
 
Improving study quality 
 
A range of measures are strongly warranted, to increase the implementation of 3Rs principles, the 
methodological quality of animal research, the reliability of results, and to overcome some of the barriers that 
currently prevent reliable extrapolation to human outcomes. 
 
Compliance with each of the 3Rs, and with the ARRIVE guidelines and other best practice standards, during the 
design, conduct and reporting of experiments, must become mandatory. Such standards should cover animal 
sourcing, housing, environmental enrichment, socialization opportunities, appropriate use of anesthetics and 
analgesics, handling, non-invasive endpoints, and a range of measures designed to minimize sources of bias, and 
to ensure methodological quality. Compliance with such standards should be a necessary condition for securing 
research funding, ethical approval, licensing of researchers, facilities and experimental protocols, and publication 
of subsequent results. Compliance would also facilitate subsequent systematic reviews.  
 
Where journal space constraints limit the description of methodological details, these should be included in 
supplementary online databases, which are now widely available (Kilkenny et al., 2009). This would also facilitate 
the transfer of alternative technologies, such as the development of new alternative methods, between 
institutions (Gruber and Hartung, 2004).  
 
To enable animal researchers and technicians to meet the necessary standards, training and continuing 
professional development in 3Rs methodologies and the design, conduct and reporting of animal research should 
be compulsory. The existing lack of focus on replacement methods (in favor of refinement methods) must be 
addressed.  
 
The adoption of measures such as these would all increase the reliability of research results, and would facilitate 
their use within systematic reviews. Prior to designing any new animal study, researchers should conduct a 
systematic review to collate, appraise and synthesize all existing good quality evidence relating to their research 
questions. Such systematic reviews should be similarly required by grant agencies, ethical review committees, 
other animal experiment licensing bodies, and journals. Systematic reviews are studies in and of themselves. In 
recognition of their intrinsic value, and their necessity for informing further research, these should also be readily 
funded by grant agencies. 
 
To ensure that all such evidence is publicly available, greater efforts must also be taken by researchers and 
editors to publish negative results. Studies that fail to show a treatment effect are often considered less 
interesting, and are consequently less likely to be published. The subsequent exclusion of such results from 
systematic reviews leads to over-estimations of treatment efficacy, and partly explains the widespread failures 
in humans, of treatments apparently efficacious in animals. 
 
Within the field of human studies, clinical trial registers allow researchers to learn about existing and prior clinical 
trials – including those with negative outcomes, before results are formally published. An international initiative 
to similarly register animal studies, and their results, is similarly warranted (Hooijmans et al., 2014). 
 
Many of these measures will require cooperation and coordination between researchers, regulators, licensing 
bodies, ethical review committees, funding bodies and journals, authors. And of course, the necessary 
willingness, among all parties, to change. 
 
If all of these measures were successfully implemented throughout the broad field of animal research, then we 
might be able to accurately predict treatment effects within the animal species under study. However, 
interspecies differences will remain in absorption, distribution, metabolism, and elimination pathways or rates, 
resulting in differing toxico- or pharmacokinetics and –dynamics, and subsequently, differences in the organ 
systems affected – and in the nature and magnitude of those effects. Such factors, which reflect the intrinsic 
complexity of living organisms, will continue to pose barriers to extrapolation to humans, that will remain 
insurmountable, in many cases. 
 
Impacts on laboratory animals 
 
Human patients are far from the only victims of poorly conducted, poorly predictive animal research. A wide 
variety of stressors have the potential to cause significant stress, fear, and possibly distress, in laboratory animals. 
These stressors may be associated with the capture of wild-sourced species such as primates, to supply 
laboratories or breeding centers; with transportation, which may be prolonged for some animals; with laboratory 
housing and environments; and with both routine and invasive laboratory procedures (see ‘Limitations of animal 
models’ previously, and Knight, 2011). An invasive procedure is any that interferes with bodily integrity, whether 
through puncture or incision, or insertion of an instrument or foreign material, as in surgical and some 
experimental procedures (Knight, 2011). 
 
A large minority of all procedures are markedly invasive. These include procedures resulting in death (whether 
or not the animals were conscious), surgical procedures (excluding very minor operative procedures), major 
physiological challenges, and the production of genetically-modified animals. Few regions report procedural 
invasiveness, but Canada does. From 1996 – 2008 inclusively, the proportion of markedly invasive procedures 
reported in Canada ranged between approximately 29 – 44% (CCAC, 2009). These were those defined by the 
Canadian Council on Animal Care (CCAC, 2009) as resulting in moderate to severe stress or discomfort (category 
D), or in severe pain near, at, or above the pain tolerance threshold of unanesthetized conscious animals (cat. E), 
compared to procedures resulting in little or no discomfort or stress (cat. B) or minor stress or pain of short 
duration (cat. C).  
  
A sizeable majority of all procedures utilize no anesthetics of any kind. Few regions report anesthetic usage, but 
Britain does. During two recent decades (1998 – 2009), the proportion of procedures conducted without 
anesthesia fluctuated between approximately 59 per cent and 69 per cent (Home Office, 2010). For example, in 
2009 at the end of this period, 66.7% of cases did not utilize any form of anesthesia. General anesthesia was 
provided throughout or at the end of terminal procedures in 9.5% of cases. In 17.1% of cases general anesthesia 
with recovery was provided, and in 6.7% of cases, local anesthesia (Home Office, 2010). 
  
To assess animal impacts further it would be helpful to know the frequency of analgesic (pain-killer) use, the 
level of correlation between markedly invasive procedures and anesthetic or analgesic use. Painful or invasive 
procedures may warrant anesthesia and/or analgesia. Animal welfare may be adversely affected when animals 
undergoing such procedures are denied these, or conversely, when they are provided without sufficient need 
(due to their potential side effects) – although this is rare in practice. It would also be helpful to study the 
prevalence of environmental enrichment and socialization opportunities. Unfortunately, such information 
remains largely unreported. 
 
Conclusions 
 
Animal research is a mechanism by which we seek to increase our understanding of the biological world. The 
major useful applications of this knowledge lie in the development of new therapies for combatting human 
diseases, and in predicting the human toxicity of chemicals used for a wide range of purposes. As we have seen 
however, the actual efficacy of animal research for these purposes is very low. This is due to a range of causes, 
some of which are – at least theoretically – amenable to change, and some of which are not. 
 
When formulating social policy pertaining to animal research, the social benefits realized are only part of the 
equation. The other major part that must be considered concerns the resources consumed by this research. The 
very substantial financial and scientific resources consumed by animal research are consequently unavailable to 
other fields, some of which – such as preventative healthcare or human clinical research – might well be expected 
to produce greater gains for public health. And as we have seen, the impacts on animals are also severe. 127 
million living non-human vertebrates were used worldwide in 2005 – the most recent year for which an evidence-
based global estimate was available. Based on figures from countries such as Canada and the UK, where these 
are published, a large minority of all procedures are markedly invasive, and a sizeable majority utilize (or at least 
report) no anesthetics of any kind. 
 
The core ethical principle underpinning modern animal experimentation regulation and policy is that the likely 
benefits of such research must outweigh its expected costs. This utilitarian harm-benefit analysis underpins all 
fundamental regulation governing animal experimentation. For example, European Directive 2010/63/EU on the 
protection of animals used for scientific purposes, which directs such animal use in all EU member states, asserts 
that it is “essential, both on moral and scientific grounds, to ensure that each use of an animal is carefully 
evaluated as to the scientific or educational validity, usefulness and relevance of the expected result of that use. 
The likely harm to the animal should be balanced against the expected benefits of the project” (EU, 2010: 37).  
 
When considering harms and benefits overall, one cannot reasonably conclude that the benefits accruing to 
human patients or consumers, or to those motivated by scientific curiosity or profit, exceed the harms incurred 
by animals subjected to scientific procedures. On the contrary, the evidence indicates that actual human benefit 
is rarely – if ever – sufficient to justify such harms. And those harms are not limited to the many millions of 
animals used. Others potentially affected include patients and consumers. The social and ethical implications are 
profound, when consumers suffer serious toxic reactions to products assessed as safe in animal studies, or if 
patients with serious conditions are denied effective clinical interventions, partly because potentially more 
efficacious research fields are under-resourced (Knight, 2011). 
 
A paradigm change in scientific animal use is clearly warranted. Instead of uncritically assuming the benefits of 
animal research, we must subject it to much more rigorous and critical evaluation. Where animal research 
continues to persist, a broad range of measures must be implemented to substantially improve its 
methodological quality and compliance with the 3Rs, and to maximize the reliability of subsequent results 
(Knight, 2011). Where such research fails to meet the harm-benefit standards expected by society, and which 
underpin legislative instruments such as Directive 2010/63/EU on the protection of animals used for scientific 
purposes, then such research should cease, with the resources consumed by it directed into more promising and 
justifiable fields of research and healthcare.  
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